Sun Pharmaceutical Industries

太阳制药工业公司

on Monday said it has launched its global innovative drug

周一表示，已推出其全球创新药物

ILUMYA

伊利姆亚

in India for the treatment of moderate-to-severe

在印度用于治疗中度至重度的

plaque psoriasis

斑块状银屑病

.

。

A novel

一本小说

biologic treatment

生物治疗

, ILUMYA (

，ILUMYA （

Tildrakizumab

特立卓利单抗

) has been endorsed widely by

) 已被广泛认可

dermatologists

皮肤科医生

in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

在美国和世界范围内，多年来一直作为一种有效且安全的治疗中度至重度斑块状银屑病的方法。

'ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,' said Kirti Ganorkar, Managing Director,

“ILUMYA 为难以控制中度至重度斑块型银屑病的患者提供了一种安全有效的治疗选择，”总经理 Kirti Ganorkar 表示，

Sun Pharma

太阳制药

.

。

Also Read:

另请阅读：

Torrent Pharma fined Rs 41 crore over alleged wrong GST refund

Torrent制药因涉嫌错误的GST退税被罚款4.1亿卢比。

Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years, he added.

他补充道，ILUMYA已经在35个国家上市，始终表现出显著且持久的皮肤清除效果，从治疗开始后不久便开始见效，并在多年内持续维持。

Live Events

现场活动

Plaque psoriasis is a

斑块型银屑病是一种

chronic autoimmune disease

慢性自身免疫性疾病

that causes the cells to reproduce very quickly. It's a type of psoriasis that causes thick, scaly patches called plaques on the skin. The global

导致细胞快速繁殖。这是一种牛皮癣，会在皮肤上引起称为斑块的厚厚鳞片状斑块。全球范围内

psoriasis prevalence

银屑病患病率

rate is around 2-3 per cent of the world population whereas in India the prevalence varies from 0.44-2.8 per cent.

率约为世界人口的2-3％，而在印度，患病率在0.44-2.8％之间。

Sun Pharma shares were trading 0.73 per cent down at Rs 1,817.90 apiece on BSE.

太阳药业的股票在孟买证券交易所每股交易价格为1817.90卢比，下跌了0.73%。

Add

添加

as a Reliable and Trusted News Source

作为可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)